Last Update 06 Apr 26

SLQT: Reset Expectations And Pharmacy Agreement Will Support Future Upside

Analysts trimmed their SelectQuote price targets by $1 to $2, citing updated assumptions around discount rates, profit margins and long term P/E expectations that indicate a more cautious outlook on the shares.

Analyst Commentary

Recent research updates point to a more measured stance on SelectQuote, with price targets trimmed by $1 to $2 as analysts revisit their assumptions around discount rates, profit margins and long term P/E levels.

Bullish Takeaways

Bullish analysts still see value in the shares even after lower targets, suggesting that revised models continue to support upside potential relative to current pricing.
Adjustments to long term P/E assumptions imply that some analysts view the company as capable of supporting a valuation that reflects an established, rather than early stage, business over time.
The willingness to refine discount rate inputs instead of abandoning coverage signals that analysts still view SelectQuote as relevant for investors tracking the sector.
Trims of $1 to $2, rather than more aggressive cuts, suggest that the core thesis around the company’s ability to execute on its business model remains intact in analyst models.

Bearish Takeaways

Bearish analysts are building in higher discount rates, which reduces the present value of future cash flows and results in lower price targets.
More cautious profit margin assumptions point to concerns about cost control and the potential for earnings to lag earlier expectations.
Lower long term P/E expectations indicate reduced confidence that the market will be willing to pay premium multiples for SelectQuote over time.
The concurrent $1 to $2 target cuts highlight a tighter margin for error on execution, with less room for operational setbacks before valuation could come under additional pressure.

What's in the News

On March 19, 2026, SelectQuote received a notice from the New York Stock Exchange that its average closing share price had been below $1.00 over a 30 trading day period, triggering a six month cure window to regain compliance with listing standards (Key Developments).
The company plans to monitor its stock price during the cure period and may consider actions that require stockholder approval if needed to address the share price deficiency, while its stock continues to trade on the NYSE subject to other listing requirements (Key Developments).
SelectQuote announced SelectQuote Local, a franchise model that uses the company’s marketing, technology, customer service, and carrier relationships to offer senior health and life insurance products through local representatives, expanding beyond its current telephonic distribution (Key Developments).
Franchise owners in SelectQuote Local can purchase rights to operate in specific geographic regions, creating a new channel for the company to reach consumers who prefer in person support while using the same product set and processes (Key Developments).
For fiscal 2026, SelectQuote issued revenue guidance of US$1.61b to US$1.71b, and separately announced that SelectRx pharmacy entered a new multiyear agreement with a long time pharmacy benefit manager partner that is described as providing more predictable economics and aligning with expectations shared on the first quarter fiscal 2026 earnings call (Key Developments).

Valuation Changes

Fair Value: $3.06 is unchanged, with the updated estimate matching the prior figure.
Discount Rate: has risen slightly from 10.23% to 11.34%, indicating a higher required return in the updated model.
Revenue Growth: remains effectively unchanged at around 5.76%, with only a very small adjustment in the updated assumptions.
Net Profit Margin: has fallen significantly from 2.01% to 0.80%, reflecting a more cautious view on future profitability.
Future P/E: has been revised higher from an already very large 1,988.36x to an even larger 5,141.44x, signaling a much higher multiple embedded in the long-term valuation assumption.

1 view

Key Takeaways

Expansion in healthcare services and technology investments boost revenue growth, margin expansion, and operational efficiency, driving higher profitability and improved cash flow.
Growing Medicare market and diversified revenue streams enhance long-term stability, reducing earnings volatility and strengthening the company's financial position.
Slowing growth, reliance on cost cuts, market volatility, and persistent balance sheet risks challenge SelectQuote's ability to sustain margins and long-term earnings expansion.

Catalysts

About SelectQuote

Operates a technology-enabled, direct-to-consumer distribution and engagement platform that sells insurance policies and healthcare services in the United States.What are the underlying business or industry changes driving this perspective?

Rapid growth of the Healthcare Services business, especially SelectRx, demonstrates strong product-market fit with recurring, high-margin revenue and significant runway for further margin expansion as scale efficiencies kick in; this positions the company for sustained revenue and EBITDA growth.
Increasing adoption of digital platforms for insurance and healthcare services, combined with SelectQuote's advanced technology and AI investments, continues to reduce customer acquisition costs and drive agent productivity, supporting higher operating margins and improved EBITDA.
The aging U.S. population and rising Medicare enrollment ensure a steadily expanding addressable market, enabling long-term top line growth opportunities across both the Medicare insurance and pharmacy segments.
Enhancement of operational efficiency through automation and process optimization, evidenced by rising agent productivity and improved revenue-to-CAC ratios, sets the stage for higher profitability and stronger operating cash flows in future years.
The company's transition toward a diversified platform with a balanced mix of immediate cash-generating healthcare revenues and more stable, recurring senior insurance cash flows reduces earnings volatility and supports improved free cash flow and balance sheet strength over time.

SelectQuote Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

Analysts are assuming SelectQuote's revenue will grow by 5.8% annually over the next 3 years.
Analysts assume that profit margins will shrink from 1.2% today to 0.0% in 3 years time.
Analysts expect earnings to reach $153.8 thousand (and earnings per share of $-0.0) by about April 2029, down from $19.6 million today.
In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 5153.6x on those 2029 earnings, up from 5.4x today. This future PE is greater than the current PE for the US Insurance industry at 11.4x.
Analysts expect the number of shares outstanding to grow by 2.07% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 11.34%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

SelectQuote's Healthcare Services (SelectRx) is experiencing slowing membership and revenue growth rates as the business matures, suggesting diminishing expansion opportunities which could limit long-term revenue growth and EBITDA margin improvement.
The company anticipates relatively flat Senior policy volumes and expects agent productivity to revert to historical norms, which may constrain future revenue growth and compress margins due to a less favorable business mix.
Margin expansion is heavily dependent on further cost optimization and automation; if technology investments or efficiencies do not adequately offset rising costs or competitive pressures, net margins and profitability targets may not be realized.
Persistent volatility and disruption in the Medicare Advantage market, including plan terminations and carrier profitability actions, expose SelectQuote to policy volume declines and lower Lifetime Value (LTV) per policy, risking the stability of earnings and cash flow.
Despite recent improvements, the company's focus on improving its balance sheet and cost of capital indicates ongoing leverage and capitalization risks; a failure to further optimize the capital structure could elevate financing costs and impede reinvestment in technology or new business lines, hindering long-term earnings growth.

Valuation

How have all the factors above been brought together to estimate a fair value?

The analysts have a consensus price target of $3.06 for SelectQuote based on their expectations of its future earnings growth, profit margins and other risk factors.
However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $5.0, and the most bearish reporting a price target of just $1.25.
In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $1.9 billion, earnings will come to $153.8 thousand, and it would be trading on a PE ratio of 5153.6x, assuming you use a discount rate of 11.3%.
Given the current share price of $0.6, the analyst price target of $3.06 is 80.3% higher. Despite analysts expecting the underlying business to decline, they seem to believe it's more valuable than what the market thinks.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on SelectQuote?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Healthcare Services And Medicare Will Boost Future Momentum Amid Risks